tiprankstipranks
Trending News
More News >
Renovaro Biosciences (RENB)
NASDAQ:RENB
Advertisement

Renovaro Biosciences (RENB) Price & Analysis

Compare
168 Followers

RENB Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

24.50%4.88%0.05%67.65%
24.50% Insiders
0.05% Other Institutional Investors
67.65% Public Companies and
Individual Investors

RENB FAQ

What was Renovaro Biosciences’s price range in the past 12 months?
Renovaro Biosciences lowest stock price was $0.26 and its highest was $2.10 in the past 12 months.
    What is Renovaro Biosciences’s market cap?
    Renovaro Biosciences’s market cap is $75.19M.
      When is Renovaro Biosciences’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Renovaro Biosciences’s earnings last quarter?
      Currently, no data Available
      Is Renovaro Biosciences overvalued?
      According to Wall Street analysts Renovaro Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Renovaro Biosciences pay dividends?
        Renovaro Biosciences does not currently pay dividends.
        What is Renovaro Biosciences’s EPS estimate?
        Renovaro Biosciences’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Renovaro Biosciences have?
        Renovaro Biosciences has 230,928,970 shares outstanding.
          What happened to Renovaro Biosciences’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Renovaro Biosciences?
          Currently, no hedge funds are holding shares in RENB

          Renovaro Biosciences Stock Smart Score

          2
          Underperform
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Technicals

          SMA
          Negative
          20 days / 200 days
          Momentum
          -75.00%
          12-Months-Change

          Fundamentals

          Return on Equity
          -67.13%
          Trailing 12-Months
          Asset Growth
          -33.89%
          Trailing 12-Months

          Company Description

          Renovaro Biosciences

          Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.
          Similar Stocks
          Company
          Price & Change
          Follow
          Cassava Sciences
          VistaGen Therapeutics
          vTv Therapeutics
          Cibus
          Cabaletta Bio
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis